Vitae Pharmaceuticals Initiates Phase II Clinical Trials for 2 Novel Compounds for Psoriasis and Cancer Conditions
29th Nov 2005, 14:38 GMT
Vitae Pharmaceuticals has initiated Phase II clinical studies with VTP- 201227 for the treatment of psoriasis and VTP-195183 to enhance immune cell levels in cancer treatments.
Vitae Pharmaceuticals Initiates Phase II Clinical Trials for 2 Novel Compounds for Psoriasis and Cancer Conditions related news:
- Vitae Pharmaceuticals Initiates Phase II Clinical Trials for Two Novel Compounds for Psoriasis and Cancer Conditions — PR Newswire: All Releases
- Vitae Pharmaceuticals initiates psoriasis and cancer trials — Pharmaceutical Business Review Online
- Provectus initiates phase I trial in breast cancer — Pharmaceutical Business Review Online
- Schering Announces Start of 3 Phase II Clinical Trials With Anti-Cancer Compound ZK-EPO — Mammography News from StratCenter.com
- Schering AG begins phase II trials of anticancer compound — Pharmaceutical Business Review Online
- Novelos to take its lung cancer treatment to late-stage trials — bizjournals.com Health Care:Pharmaceuticals headlines
- Progenics Pharmaceuticals Initiates Clinical Trial of Viral-Entry Inhibitor PRO 140 in HIV-Infected Patients — StratWire - Business of Healthcare NewsFeed
- Coley initiates late-stage anticancer drug trials — Pharmaceutical Business Review Online
- Provectus Begins Phase 1 Breast Cancer Trial — Surgery News from StratCenter.com
- InSite Vision Announces Positive Top-Line Results from 1st of 2 Pivotal Phase 3 Clinical Trials — Pharmaceuticals News from StratCenter.com
Latest news from Operations-Related News from StratCenter.com:
- Senior Housing Properties Trust Announces Proposed Public Offering of 5 mln Common Shares
- King Not Loving Its Shareholders
- Sepracor says asthma drug data is favorable
- Sepracor Presents Data on Asthma Drug
- Dr Reddy's Registers to List Shares
- PolyMedica Corp CEO to Ring the NASDAQ Stock Market Opening Bell
- Biovail to Present at the CSFB 2006 Healthcare Conference
- Genelabs reports lower Q3 loss
- Solexa posts narrowed Q3 loss
- Abbott's Humira Positive in 2 Studies